Cetuximab, an epidermal growth factor receptor (EGFR) inhibitor that belongs to the monoclonal antibody class, is widely used to treat head and neck squamous cell carcinoma and in patients with RAS wild-type metastatic colorectal cancer. Here, EGFR is linked to head and neck squamous cell carcinoma.